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INTRODUCTION: We will evaluate the feasibility of a randomised controlled trial (RCT) to 2 
estimate the effectiveness and cost-effectiveness of a rehabilitation intervention on pain, 3 
function and health-related quality of life following neck dissection (ND) after head and neck 4 
cancer (HNC). 5 
 6 
METHODS AND ANALYSIS:  This is a pragmatic, multicentred, feasibility study. Participants 7 
are randomised to usual care (control) or usual care plus an individualised, rehabilitation 8 
programme (GRRAND Intervention). Adults aged over 18 with HNC for whom neck dissection 9 
is part of their care will be recruited from specialist clinics. Participants are randomised in 1:1 10 
ratio using a web-based service. The target sample size is 60 participants. Usual care will be 11 
received by all participants during their post-operative inpatient stay consisting standard NHS 12 
care supplemented with a booklet advising on post-operative self-management strategies. 13 
The GRRAND intervention programme consists of usual care plus up to six individual 14 
physiotherapy sessions including neck and shoulder range of motion and progressive 15 
resistance exercises, advice and education. Between sessions participants will be advised to 16 
complete a home exercise programme. The primary outcome is to determine recruitment and 17 
retention rates from study participants across sites. Outcomes will be measured at six and 12 18 
months. Participants and physiotherapists will be invited to an optional qualitative interview 19 
at the completion of their involvement in the study. The target qualitative sample size is 15 20 
participants and 12 physiotherapists. Interviews aim to further investigate the feasibility and 21 
acceptability of the intervention and to determine wider experiences of the study design and 22 




ETHICS AND DISSEMINATION: Ethical approval was given on 29 October 2019 (National 25 
Research Ethics Committee Number: 19/SC/0457). Results will be reported at conferences 26 
and in peer-reviewed publications.  27 
 28 
TRIAL ISRCTN REGISTRATION NUMBER: 11979997 29 
STATUS: trial recruitment is ongoing and is expected to be completed by 30th Aug 2021. 30 
 31 
Strengths and limitations of this study:  32 
• GRRAND-F (Getting Recovery Right After Neck Dissection) is a pragmatic, 33 
multicentred, randomised control feasibility trial. 34 
• We will evaluate whether it is feasible to run a RCT to assess the effectiveness and 35 
cost-effectiveness of a rehabilitation intervention in improving pain, function and 36 
health-related quality of life following ND after HNC. 37 
• The primary outcome is recruitment and retention rates.  38 
• The qualitative sub-study will explore the wider experiences and perceptions of the 39 











Head and neck cancer (HNC) affects 700,000 people worldwide and over 11,000 in the UK 49 
annually[1-3]. HNC refers to neoplasms at different anatomical sites. Within the UK, tumours 50 
of the oropharynx are the most common and have seen a two-fold increase in incidence over 51 
the last 20 years, largely attributed to human papillomavirus (HPV)[4,5]. During this time 52 
there has also been a 30% increase in oral cancer[4-6]. While there has been a significant 53 
increase in HNC, prognosis and survival in the UK continues to improve[4,6]. Therefore the 54 
proportion of people living with the effects of this cancer and its treatment continues to 55 
increase.  56 
 57 
The treatment pathway for HNC is complex, due to the varied anatomical sites of disease and 58 
the needs of the patient. Treatment for HNC requires treatment of the primary site, as well 59 
as the neck when there is spread to the lymph nodes or high probability of spread. Historically 60 
almost all patients received a neck dissection (ND). With the advent of chemo-radiotherapy 61 
as a curative treatment, less patients require a ND. However even with this approach, up to 62 
20% of patients require a ND due to residual disease[6]. Side-effects from surgery can be 63 
significant, including swallowing problems, neck and shoulder problems, difficulties sleeping, 64 
fatigue and anxiety[7,8].  65 
 66 
Post-operative complications are common following ND[8-11]. Early complications can 67 
include shoulder pain and infection. Late complications may not appear until three months 68 
post-treatment, and can continue to present over five years[12,13]. These complications 69 
include shoulder movement dysfunction, speech, swallowing and musculoskeletal problems 70 
such as cervical contracture and muscle wastage[12]. Psychosocial complications are also 71 
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highly prevalent post-operatively, predominantly fatigue, anxiety, depression, sleep 72 
disturbance and social isolation. Sequelae of shoulder dysfunction and psychosocial 73 
complications are strongly associated with reduced return to work, with up to 50% of patients 74 
ceasing working due to shoulder disability alone[10,14]. 75 
 76 
Rehabilitation was one of 22 key questions in the 2016 National Institute for Health and Care 77 
Excellence (NICE) Clinical Guideline[15] on the management of HNC. The guideline 78 
recommends clinicians “consider progressive resistance training for people with impaired 79 
shoulder function, as soon as possible after ND”. The review noted that this evidence was 80 
from small trials with a high risk of bias. The review also highlighted a knowledge gap on how 81 
to rehabilitate HNC patients’ wider side-effects. The NICE guideline concluded that a 82 
prospective randomised trial was required to understand how best to promote recovery 83 
following HNC, making this a recognised National Health Service (NHS) research priority[15]. 84 
 85 
Currently there is no national standard best practice for rehabilitation following HNC. Our 86 
study development work[16] and feedback from patient and public (PPI) representatives has 87 
shown that physiotherapy practice varies across the UK. The findings suggested that 88 
rehabilitation in the form of physiotherapy is not routinely available to patients with HNC, in 89 
either in-patient or outpatient settings[16]. When rehabilitation is offered it is often not 90 
evidence-based, and targets acute respiratory care, range of motion (ROM) exercises for the 91 
neck and shoulder, and advice on positioning of the upper limb and shoulder girdle[15]. A 92 
booklet may be provided to supplement this treatment. Outpatient treatment is minimal, and 93 
most commonly reactive, driven by patient request. Whilst trials have begun to provide 94 
indicative findings on different rehabilitation strategies for this population[17,18], the current 95 
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evidence-base is limited in quality and only focuses on shoulder exercises. There remains a 96 
gap in knowledge on how to rehabilitate patient’s wider side-effects following surgery for 97 
HNC such as fatigue, anxiety, poor sleep and return to work. Consequently, both Cochrane[19] 98 
and NICE[15] concluded that further high-quality research is needed to determine how best 99 
to promote recovery for shoulder function, quality of life and cost-effectiveness of treatment.  100 
 101 
This study will evaluate whether it is feasible to conduct a RCT to assess the effectiveness and 102 
cost-effectiveness of a multi-modal rehabilitation intervention in improving pain, function 103 
and health-related quality of life following ND after HNC. In addition to investigating the 104 
feasibility of an enhanced rehabilitation intervention following HNC ND, this trial will also 105 
standardise usual care. 106 
 107 
METHODS AND ANALYSIS 108 
 109 
Trial Design 110 
A mixed-methods feasibility study investigating the design of a RCT to test the clinical and 111 
cost-effectiveness of usual care and an individualised, rehabilitation programme (GRRAND) 112 
compared to usual care alone in patients undergoing a ND for HNC. The study flow chart is 113 
presented as Figure 1.  Table 1 presents a summary of trial objectives, outcome measures and 114 
time points.  115 
 116 
Eligibility 117 
Participants are eligible to take part in the trial if they fulfil the eligibility criteria listed in Box 118 
1. All patients having a ND regardless of other associated procedures are eligible. Head and 119 
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neck cancer can arise at a number of anatomical sites and a ND is often combined with 120 
additional treatment such as radiotherapy to the primary site. This reflects the expected 121 
practice in HNC treatment [15]. We will record the location of cancer, specific surgical 122 
interventions and planned additional treatments such as radiotherapy, to ascertain the profile 123 
of the recruited ND cohort. This will provide information to aid sample size calculations, 124 
stratification approaches and analysis plans for confounders/modifiers in a definitive trial.   125 
 126 
Recruitment 127 
Potential participants will be identified from UK NHS hospital trusts as requiring a ND as part 128 
of their treatment, and will be approached by a member of the clinical team to ask whether 129 
they would like to know more about the GRRAND-F study.  130 
 131 
They will be asked to read the Patient information sheet (PIS) and to discuss their potential 132 
participation with anyone who they feel would provide useful advice. Potential participants 133 
will also be provided with contact information for the research team who will be able to 134 
answer any questions relating to the study. The number of patients provided with the PIS will 135 
be recorded to monitor the number of patients who are approached. 136 
 137 
Eligible patients who agree to participate will then be asked to provide their written informed 138 
consent (Supplementary File 1).  139 
 140 
Randomisation, Blinding and Allocation Concealment 141 
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Following the completion of the consent process  baseline data will be collected.  Participants 142 
will then be randomised once their eligibility has been confirmed post-operatively prior to 143 
hospital discharge. 144 
 145 
Participants will be randomised in a 1:1 ratio using the centralised web-based randomisation 146 
service provided by Oxford Clinical Trials Research Unit (OCTRU). Randomisation will be 147 
undertaken using minimisation to ensure balanced allocation of participants across the two 148 
treatment groups, stratified by hospital site and spinal accessory nerve sacrifice. 149 
 150 
The minimisation algorithm will incorporate a non-deterministic element and will be seeded 151 
using simple randomisation to prevent predictability in the early stages of the study. 152 
Due to the nature of the intervention, participants and clinicians delivering physiotherapy will 153 




Usual Care 158 
Usual care will be received by both control and experimental intervention groups.  159 
 160 
As part of usual care, all participants will receive the same in-patient rehabilitation 161 
programme, commencing day one post-operatively (or next physiotherapy working day), 162 
consisting of: 163 
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(1) Advice to practise simple ROM exercises for the face and neck for the purpose of 164 
preventing the onset of post-surgical contracture and optimising swallowing and shoulder 165 
movement.  166 
(2) Respiratory care, targeting sputum clearance and breathing control. 167 
(3) Education on body positioning to reduce pressure and pull on the shoulder girdle, oral 168 
health to reduce food pocketing in the mouth, and pain management and pacing activities 169 
to optimise levels of comfort and function.  170 
 171 
The content, dosage and timing of in-patient physiotherapy contact will be recorded. 172 
 173 
Reflecting usual care, on discharge participants will receive a booklet providing advice on 174 
post-operative self-management strategies including exercise, pain management, return to 175 
work and activities of daily living. This has been developed by the multidisciplinary trial team 176 
and collaborations with two of the participating NHS centres in Birmingham and Oxford to 177 
ensure that the information is standardised. Reflecting current practice, once discharged from 178 
hospital, physiotherapy will not be routinely provided to these participants. 179 
 180 
Experimental intervention 181 
Participants randomised to this group will receive the same in-patient rehabilitation 182 
programme as participants in the Usual Care Group PLUS an individualised rehabilitation 183 
programme. This will be delivered by a GRRAND-F-trained physiotherapist in an outpatient 184 
setting. In the event that the participant is still an in-patient, this will be commenced in 185 
hospital and continued, post-discharge, in an outpatient setting. The frequency to which this 186 
change of setting occurs will be recorded as part of the feasibility outcomes.  187 
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At the initial consultation, physiotherapists will assess the participant to identify modifiable 188 
physical and psychosocial factors associated with poor recovery following HNC surgery. These 189 
may include: muscle weakness, limited ROM, reduced sensation, pain and fear avoidance 190 
beliefs. Based on this assessment, physiotherapists will prescribe from a pre-specified range 191 
of rehabilitation options (see Figure 2).  192 
 193 
Programmes will be individualised to contain one, several, or all of the treatment options, 194 
dependent on participant’s needs. Participants will also be provided with a home exercise 195 
programme to supplement face-to-face sessions.  196 
 197 
Individualised Rehabilitation Options 198 
(1)      ROM exercises targeting muscles and joints of the face, neck and shoulder impacted by 199 
ND. The purpose of these exercises is the prevention of post-surgical contracture, and the 200 
maintenance of swallowing and upper limb mobility.  201 
(2)     Progressive resistance exercises, targeting strengthening of the neck and shoulder. 202 
Resistance loads will initially be set at a moderate level of exertion (based on the modified 203 
Borg scale of perceived exertion [20]) to permit progression, enhance motivation and 204 
adherence, and reduce the possibility of symptom flare-up. Resistance will consist resistance 205 
bands at the shoulder and isometric resistance provided by the participant’s hand for neck 206 
and temporomandibular joint exercises.   207 
Exercises will be progressed by increasing the resistance load, speed, number of repetitions 208 
and sets or by progressing the range in which the exercise is completed and through the 209 
introduction of weight-bearing exercises through the upper limb. Additionally, the exercises 210 
will become increasingly ‘task specific’, targeting participant’s specific functional goals. 211 
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(3)     Education and advice on a number of recognised potential post-operative complications 212 
including: 213 
•          Positioning limbs to prevent joint contractures  214 
•          Oral health particularly for patients following upper cervical/head/oral surgery  215 
•          Pain management for both early and later post-operative stages through positioning, 216 
taking prescribed analgesics and pacing/behaviour modfication.   217 
•          Scar management. 218 
•          Exercise adherence and return to function with fatigue management and pacing of 219 
activities  220 
•          Promote independence and confidence to return to normal activities of daily living, 221 
work, and social pursuits.  222 
 223 
This will be delivered through the introduction of techniques of goal setting, fear avoidance, 224 
pacing and fatigue management, behaviour modification and graded activity. This has been 225 
successfully taught and delivered by the research team in previous NIHR trials (BOOST[21], 226 
DAPA[22]), to provide a basis for this new intervention. Advice will be provided through 227 
discussion during consultations and re-enforced with worksheets designed by the multi-228 
disciplinary trial team. 229 
 230 
The intervention may be modified in the development phase of the trial. The intervention 231 
will be finalised prior to the main trial. If there are no substantive changes, participants will 232 
contribute to the main trial analysis.  233 
 234 
Delivery  235 
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The experimental intervention will be delivered a maximum of six sessions over a six-month 236 
period. The design will enable assessment of how many sessions are required. The first 237 
session will aim to occur within 14 days of surgery. Reflecting normal NHS practice, the initial 238 
session will be 60 minutes, and subsequent sessions up to 45 minutes in duration. The 239 
physiotherapist, in collaboration with the participant, will agree the spacing of sessions, 240 
reflecting normal clinical practice. This spacing will allow for maximum progression of the 241 
intensity of exercise over a time period sufficient to (hypothetically) produce an improvement 242 
in outcome. Treatment options may also be added or removed at each session, in line with 243 
the participant’s current treatment progress and health status.  244 
 245 
The timing and spacing of sessions around additional treatments such as radiotherapy and 246 
chemotherapy will be determined by the participant and physiotherapist. Through this, if the 247 
participant or physiotherapist feel that the intervention is not appropriate due to 248 
radiotherapy/chemotherapy side-effects such as fatigue, pain or nausea, the GRRAND 249 
intervention will be delayed until symptoms reduce. Alternatively, if the participant and 250 
physiotherapist agree that the GRRAND intervention would be beneficial alongside such 251 
treatments, this will be permitted. This reflects the individualised nature of the intervention.  252 
 253 
Contamination 254 
The GRRAND-F physiotherapists who deliver the experimental intervention sessions where 255 
possible will not deliver physiotherapy to those in the control group (and vice versa). The 256 
details of the physiotherapists delivering sessions will be recorded and reviewed to monitor 257 
this risk of contamination. Due to the interventions being individualised and delivered in an 258 
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outpatient setting, there is a low risk of participants sharing their knowledge and experience 259 
between groups, further minimising the risk of between-group contamination.  260 
 261 
Co-Interventions 262 
Respecting the pragmatic nature of this study design, participants from either group will not 263 
be asked to desist from receiving any other forms of treatment during the trial or follow-up 264 
periods. If a participant receives additional treatment, the details of the treatment received 265 
and the reasons for administering will be collected. 266 
 267 
Quality Assessment 268 
The trial will be monitored and audited in accordance with the current approved protocol, 269 
good clinical practice[23], relevant regulations and standard operating procedures (SOPs). 270 
All designated physiotherapists who deliver usual care will be taught the standardised control 271 
intervention procedures.  272 
 273 
Physiotherapists delivering the GRRAND intervention will attend a face-to-face training 274 
session where they will be taught the intervention and processes involved by a member of 275 
the GRRAND-F team who developed the intervention (TS, VG). Each intervention 276 
physiotherapist will be monitored during a site visit at their third/fourth session. Sessions will 277 
be monitored against the protocol to determine whether there are issues around fidelity, 278 
contamination across groups or adherence/compliance of participants. Where further 279 
training or further monitoring visits are required, these will be instigated following these 280 





Data will be clinical and participant-reported and collected using questionnaires at baseline 284 
and six months post-randomisation. Data will also be collected for those participants who 285 
reach 12-month follow-up during the data collection phase. This is estimated to be applicable 286 
for up to 50% of the cohort. Data will be collected alongside routine clinical appointments at 287 
each site. A primary end-point of six-months post-randomisation was chosen to provide a 288 
signal on clinical outcomes after completing the intervention. The 12-month data provides 289 
data to assess the risk of attrition and missing data at 12 months, which will assist with the 290 
development of the definitive trial if it proves to be feasible.  291 
 292 
Baseline Assessment 293 
Baseline data will be collected prior to randomisation once consent has been obtained, 294 
typically during the pre-operative assessment. Data collection is described in Table 2.  295 
 296 
Outcome data to be collected at each of the data collection intervals are listed below.   297 
• Shoulder pain and function measured using the well-validated Shoulder Pain and 298 
Disability Index (SPADI)[24, 25].  299 
• Pain measured using the SPADI 5-item Pain Sub-scale[25] and a Numerical Rating Scale. 300 
• Function measured using the SPADI 8-item Function sub-scale[25] 301 
• Pain medication details and usage relating to head, neck and shoulder.  302 
• Chemotherapy and radiotherapy treatment provision. 303 
• Health-related quality of life measured using the EQ-5D-5L score[26] and the EORTC 304 
questionnaires (C30 (core)[27] and H&N43 (head and neck specific)[28,29]). 305 
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• Health resource use questionnaire (collection of health resources for computation of 306 
direct medical, direct nonmedical and indirect costs); additional out-of-pocket expenses; 307 
and work absence.  308 
• Physical performance measures including goniometer-measured shoulder and neck 309 
active ROM and hand-held dynamometer-measured grip strength will be measured by 310 
an appropriately trained member of the research team. 311 
•    Adverse events: such as prolonged delayed onset muscle soreness, swelling and wound 312 
irritation.  313 
 314 
Follow-up procedures 315 
Data will be collected from participants at six and 12-months (if applicable) from date of 316 
surgery with a target of +/- one month, at their routine NHS check-up appointments. If 317 
participants do not attend their follow-up appointment, they will be contacted by telephone, 318 
and, if appropriate, sent the questionnaires to complete. The study team will attempt to 319 
telephone these participants on up to two occasions. If these methods fail, we will categorise 320 
the participant as a ‘non-responder’ for that time-point only. The data collection schedule is 321 
presented in Table 2. 322 
 323 
Outcome Measures 324 
Feasibility outcome data to be collected will include: 325 
• Screening log numbers of eligible patients, including reasons for exclusion/non-326 
participation.  327 
• Recruitment numbers and rate; overall and per site. 328 
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• Protocol adherence, including fidelity to control and experimental interventions using 329 
treatment logs, timing and location of intervention delivery (in particular the first session) 330 
alongside frequency of physiotherapy contact. This will assist in assessing both potential 331 
between-group contamination and intervention delivery. We will also monitor the 332 
intervention delivery as part of the Quality Assurance (QA) monitoring visits. The findings 333 
of these visits will provide data on intervention location, fidelity to the protocol, and 334 
barriers or facilitators to provision across the sites.    335 
• Follow-up completion rate and overall study retention in each study arm for the outcome 336 
measures highlighted above. 337 
 338 
The primary and secondary outcome measures for this trial are presented in Table 1.  339 
 340 
Data Analysis 341 
 342 
Sample Size 343 
As this is a feasibility study which is not aimed to assess treatment effects, we have not 344 
undertaken a formal power sample size calculation. 345 
 346 
Sixty participants will be recruited, based on Teare et al’s recommendation[30] that between 347 
50 and 70 are required when continuous scale data outcomes are to be collected. This 348 
assumes a 10% drop-out. This will also provide sufficient data to answer our feasibility 349 
objectives with 30 participants from each group recruited. Based on 2017 data from two of 350 
the participating sites, approximately 160 potentially eligible participants were identified. 351 
Based on a conservative judgement of 45% recruitment rate for this rehabilitation trial with 352 
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this cohort[19,31,32], over 60 participants could be recruited within a 12-month period. This 353 
is within the required number to conduct this study. 354 
 355 
Statistical Analysis 356 
Recruitment and follow-up rates are the main drivers for the feasibility design on the basis 357 
that unless reasonable rates can be achieved no formal trial will be possible. Recruitment rate 358 
will be calculated as the number of participants randomised as a proportion of eligible 359 
participants.  Rates will be estimated based on data collected and a 95% confidence interval 360 
determined for these measures. The rate of incomplete information either due to drop-out 361 
to the interventions or non-completion of the outcome measures will be based on the 362 
number of participants randomised. The statistical analysis will also estimate, with 95% 363 
confidence intervals, the parameters required for a formal power calculation, particularly the 364 
standard deviation of potential outcome measures.  365 
 366 
If the estimated recruitment and follow-up rates are such that a multicentre definitive trial is 367 
possible no formal analysis will be undertaken and data from the feasibility will be locked and 368 
carried over into the definitive trial, where funding for the definitive trial has been obtained. 369 
In this case no formal analysis of treatment efficacy will be undertaken. The definitive trial 370 
will be planned based on the data collected during this feasibility study. The mean difference, 371 
standard deviation and effect size with between-group inferential statistical analyses will be 372 
estimated to determine direction and magnitude of effect and to inform a power calculation 373 
for a definitive trial. 374 
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The ‘traffic light’ system will be used as a guide for progression to a definitive trial (Table 375 
3)[33].If any of the criteria are not met, these will be discussed by the Trial Steering 376 
Committee (TSC) to decide if a definitive trial is feasible.  377 
 378 
Descriptive statistics will be used to describe the demographics between the two groups. 379 
Clinical outcome data will be reported depending on the type of variable: for continuous 380 
variables the means and standard deviation in each group (or median and interquartile range 381 
if non-normally distributed) together with the unadjusted and adjusted difference in means 382 
and corresponding 95% confidence intervals with analysis of covariance, adjusting for 383 
baseline values (where appropriate) and stratification factors; for categorical variables, the 384 
number and percentage of participants in each category will be reported and unadjusted and 385 
adjusted odds ratios (for binary outcomes) together with their 95% confidence intervals will 386 
be reported. 387 
 388 
All results will be based on the intention-to-treat population. Protocol deviations will be 389 
reported as these are an important part of the feasibility assessment when planning the 390 
definitive trial. 391 
 392 
Health Economics 393 
Data on health care utilisation will be collected but not analysed. To answer the feasibility 394 
questions related to the health economic perspectives, we will test the completion of the 395 
health resource use questionnaire and will present the data descriptively.  396 
 397 
Data Management 398 
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All data will be processed according to the Data Protection Act 2018[23,34,35] and all 399 
documents will be stored safely in confidential conditions. Trial-specific documents, except 400 
for the signed consent form and contact details, will refer to the participant with a unique 401 
study participant number and initials only. Participant identifiable data will be stored 402 
separately from trial data. 403 
 404 
Qualitative Investigation 405 
The embedded qualitative study will assess the feasibility and acceptability of the 406 
experimental and control interventions from the perspectives of those delivering 407 
(physiotherapists) and receiving (participants) the interventions. The format and delivery of 408 
the qualitative interviews are based on parameters successfully implemented in previous 409 
trials conducted by the research team (BeST[36], BOOST[21], PROSPER[37], SARAH[38]), and 410 
UK trials involving cancer patients[39]. Specifically, participant opinion and experience of 411 
study recruitment, intervention content, timing, and accessibility and barriers and facilitators 412 
to adherence will be sought. Qualitative themes identified will be used to modify the content 413 
and delivery of a future definitive trial. 414 
 415 
Recruitment 416 
Fifteen participant interviews will be conducted, involving 10 participants from the 417 
experimental intervention group and five from the control group. Based on our previous trial 418 
work[36,38], this sample size is expected to ensure data saturation across both groups, 419 




All participants will be given a brief explanation of the interviews during the initial consent 422 
process. Those willing to be interviewed will indicate permission to be contacted by the 423 
qualitative researcher on the Consent Form (Supplementary File 1). It will be clarified that 424 
not all willing participants may be required for the interview study.  425 
 426 
Participants who have agreed to be contacted for the interview will be purposively sampled 427 
by the qualitative researcher to ensure the 15 interview participants are demographically 428 
representative of the full study sample. Targeted demographics include age, ethnicity, 429 
employment status, and extent of ND. We estimate that the sample will include more males 430 
than females because approximately 70% of HNC cases in the UK in males.[40] We aim to 431 
invite two males for every one female we interview. However, if we are restricted in the 432 
number of participants available for interview, we will interview as many as available. We will 433 
highlight the sex of participants as part of our interpretation of our qualitative analysis. 434 
 435 
The qualitative researcher will telephone the sampled participants, and answer any questions 436 
they may have about taking part in the interviews. If the participant agrees to take part, a 437 
time and date convenient to the participant will be arranged for an interview. Interviews will 438 
be conducted face-to-face, and occur at a location convenient to the participant, most likely 439 
in their own home.  440 
 441 
A minimum of one physiotherapist who delivered the experimental intervention and one 442 
physiotherapist who delivered the control intervention will be interviewed from each site, 443 
until data saturation is reached. This is anticipated to occur within a maximum of 12 444 
interviews. Each physiotherapist will be asked to read the clinician qualitative study PIS, and 445 
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then to complete a Consent Form (Supplementary File 2). Physiotherapists who consent to 446 
participate will be contacted to arrange a suitable time to conduct a telephone interview.  447 
 448 
Data collection 449 
Interviews will be conducted four to six weeks after a participant’s final physiotherapy 450 
session. This cross-sectional time point allows exploration of the participant’s study 451 
experience and adherence to home exercise in a reasonable recall period. Participant 452 
interviews will take up to 90 minutes. The physiotherapist interviews will take 15 to 30 453 
minutes and will be completed  within four weeks of intervention completion.  454 
 455 
We conducted a brief literature review of evidence into the biopsychosocial barriers and 456 
facilitators for this patient group to return to their daily activities with acceptable quality of 457 
life. In parallel, we attended HNC patient rehabilitation groups to deepen our understanding 458 
of the patient perspective. The themes identified from the literature review and patient 459 
groups informed the semi-structured interview guide and framework. The qualitative 460 
researcher presented these to our PPI representatives and clinical experts and refined 461 
accordingly. The refined interview guide is provided in the Supplementary File 3. The 462 
interview schedule will be structured in alignment with the guidance for the qualitative 463 
exploration of intervention acceptability recently published in the BMJ [41]. Interviewees will 464 
have the opportunity to suggest and/or discuss additional questions. Interviews will be audio 465 
recorded, and independently transcribed.  466 
 467 
Data analysis 468 
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Transcriptions will be managed using NVIVO software[42]. Qualitative researcher (BF) will 469 
analyse the data using framework analysis[43]. The analytical framework will be informed by 470 
our evidence synthesis of the biopsychosocial rehabilitation and behaviour change literature 471 
and refined through consultation with PPI and clinical experts.  After the coding of each 472 
transcript the working framework will be discussed with patient, clinical and research team 473 
members to reduce researcher bias and strengthen the framework’s reliability. The final 474 
framework will include data from participants and physiotherapists and will be triangulated 475 
with quantitative data. We will produce and publish a framework of understanding for the 476 
intervention and trial progression. 477 
 478 
Trial Status 479 
The trial is funded for 24 months commencing in September 2019. Recruitment is expected 480 
to be complete by October 2020 with the final follow-up visit completed by April 2021. The 481 
trial will be completed by 31st August 2021. Due to the COVID-19 outbreak in the UK from 482 
March 2020, the trial timelines are expected to be extended.  483 
 484 
Protocol changes resulting from COVID-19  485 
The protocol was amended to reflect the NHS service delivery changes secondary to COVID-486 
19. These amendments include allowing intervention delivery to have the option of video 487 
consultations in line with local NHS Trusts’ policies. The change to online consultations has 488 
been reflected in the addition of eligibility criterion ‘When the hospital is only providing 489 
video consultation physiotherapy sessions, does the patient have access to the internet 490 
through a computer or tablet’. Video-delivered interventions will be monitored via video 491 
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link using NHS software. Qualitative interviews will now be conducted via telephone for 492 
both patients and physiotherapists.   493 
Follow up data collection via telephone, and postal questionnaire data collection options 494 
have been added to minimise the need for participant hospital attendance. The study team 495 
will attempt to contact these participants on up to two occasions to remind them to 496 
complete the questionnaires. If these methods fail, we will categorise the participant as a 497 
‘non-responder’ for that time-point only. Qualitative data will now be collected using 498 
telephone interviews for all groups.  499 
We plan to recruit to recruit an additional three participants to replace the participants 500 
recruited pre-COVID who were unable to adhere to the intervention due to the emergency 501 
changes in service provision. 502 
 503 
Patient and Public Involvement 504 
Patient involvement began during protocol and intervention development and continues 505 
throughout the trial. A patient-member will attend all TSC meetings. The same patient-506 
member is a co-investigator, providing insights into the trial conduct, particularly on data 507 
collection processes, and will help interpret the findings to inform on the implications of the 508 
research during the trial’s dissemination phase. 509 
 510 
ETHICS AND DISSEMINATION 511 
Ethical approval was gained from the South Central (Oxford B) Research Ethics Committee. A 512 
TSC was appointed to independently review the data on safety, protocol adherence and 513 
recruitment to the trial. Direct access will be granted to authorised representatives from the 514 
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sponsor and host institution for monitoring and/or audit of the trial to ensure compliance 515 
with regulations. Anonymised data will be shared outside the research team when required. 516 
Researchers outside the trial team may formally request for a specific data set as per the Data 517 
Management Plan. All requests will need to be approved by the TMG. 518 
 519 
Reporting of the trial will be consistent with the CONSORT 2010 Statement and its various 520 
extensions (pilot and feasibility trials, patient reported outcomes and non-pharmacological 521 
interventions)[44] and Template for Intervention Description and Replication (TIDieR) 522 
guidelines[45]. A summary of the results and trial materials will be made available via the trial 523 
website on completion of the trial. We will submit the final report to a peer-reviewed 524 
academic journal.  525 
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Box 1: GRRAND-F Eligibility Criteria  
Inclusion Criteria  
• Aged 18 years and above  
• Being treated for HNC in whom a ND is part of their care  
• Willing and able to provide informed consent  
• Able to understand written English 
• Participant is willing to attend the physiotherapy outpatient department if randomised to 
the experimental intervention arm (GRRAND-F intervention) 
• Who remain eligible post-operatively when reviewed prior to randomisation  
 
Exclusion Criteria  
• If treatment is palliative (expected survival six months or less) 
• Those with a pre-existing, long-term neurological disease affecting the shoulder e.g. 
hemiplegia 
























Table 1: GRRAND-F objectives, outcome measures and measurement time-points 
Objectives Outcome Measures  Time-points 
Primary Objective   
To determine recruitment and 
retention rates from study 
participants across sites. 
Study recruitment screening logs, 
consent forms and logs of data 
collection forms completed at each 
time-point. 
six months and 12 
months (for those 
participants who 
reach this time point 
within the study 
window). 
Secondary Objectives   
To determine potential risks of 
intervention contamination. 
Intervention logs and qualitative 






To determine feasibility and 
acceptability of the intervention 
from patient and physiotherapist 
perspectives. 
 
Intervention log, cross-over event as 
reported in protocol deviation forms, 
attrition rate and ‘did not attend’ 
rates for intervention. Qualitative 




To estimate the sample size 
calculation for a definitive trial. 
Expected primary and secondary 
outcome measure: Shoulder Pain and 
Disability Index (SPADI; overall and 
pain and function sub-scales); EQ-5D-
5L; EORTC quality of life questionnaire 
(C30 core and disease-specific 
H&N43); health resource use 
questionnaire; adverse events; 
shoulder/neck range of motion and 
grip strength. 
At the end of the trial. 
To determine wider experiences 
and perceptions of the study 
design from a patient and 
physiotherapist perspective. 



















Age (years)      
Gender      
Weight (kg)/(stone/lbs)      
Height (cm)/(ft/inches)      
Ethnicity      
Drinking status      
Smoking status      
Primary cancer site      
Stage of tumour      
Neck nodal status      
Pre-existing shoulder or neck 
musculoskeletal disorder 
     
Hand dominance      
AMTS      
List of medical co-morbidities      
Employment status and current 
occupation (when appropriate) 
     
Shoulder Pain and Disability Index 
(SPADI) 
     
Numerical rating scale pain      
EQ-5D-5L      
EORTC QLQ-C30      
EORTC QLQ-H&HN43      
Physical performance measures      
Pain relief medication list      
Complications, AE, SAE details of 
accident & emergency attendances 
and hospital admissions 
     
Operation date      
Operative procedure (Level of ND)      
Location of HNC      
Accessory nerve sacrificed      
ASA grade      
Pathology results      
Pre-operative cancer head and neck 
treatment 
     
Chemotherapy and radiotherapy 
treatment provision 
     
Intervention fidelity and cross-over 
logs 
     
Physiotherapy intervention log 
(physiotherapist completed) 
     
Home exercise diary (participant 
completed) 
     
Health economic/Health utilisation 
questionnaire 
     
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Table 3: Progression criteria for the GRRAND-F Trial. 
 
 Green (Go) Amber (Amend) Red (Stop) 
Recruitment 60 participants recruited 
within 12 months 
40-59 participants 
recruited within 12 
months 
<40 participants 
recruited within 12 
months 
Consent ≥40% of potentially 
eligible participants 
20-39% of potentially 
eligible participants 















Contamination <5% participants in 
control group received 
GRRAND-F intervention 
5-10% participants in 
control group received 
GRRAND-F 
intervention 
>10% participants in 
control group received 
GRRAND-F 
intervention 
Data Completion <15% missing data at 6-
month follow-up 
15-30% missing data >30% missing data 
Retention <20% attrition at 6 
month follow-up 
20-50% attrition at 6 
month follow-up 






Supplementary File 3: Qualitative Interview guide 
Contents 
- GRRAND-F patient  
- GRRAND-F physio 
- Care as usual patient 




Introduction and rapport build before beginning recording. No right or wrong answers, 
take you time we want to learn as much as we can from you. You are the experts. Feel free to 
change your mind as we go along sometimes being asked different questions can make us 
realise we think different things. Please ask me questions before we begin or as we are 
chatting, this is not a formal interview it is just us talking to understand your experience. I am 
an independent person and my only aim to find out what is the best way we can help people 
rehabilitation after NC. 
 
 
1. Do you remember at what point you were approached about being part of this study?  
a. PROBE: cancer context (diagnosis), post-operative context and now continuing with 
the rest of their lives context (mortality, fear, job strain etc) 
b. How were you feeling?  
 
2. Can you tell me what you first thought about participating in a study like this?  
a. PROBE: positive (benefits) or negative (concerns i.e. volume of contact query) 
b. Can you recall anything that put you off agreeing to be part of the study?  
c. And / or was there anything, in particular, which made you keen to participate? 
 
3. When you were approached about the study, were told that you might receive one type of 
programme or you might receive a different type? Can you tell me about these options? 
a. What can you remember? 
b. What did you think/feel about these options? 
 
4. When you were discharged from hospital, were you given a booklet of physiotherapy 
exercises to take home with you? Here is a copy - Show example.  
a. Can you remember the booklet?  
b. Did this help you to perform your physiotherapy at home?  
c. Useful? 
d. Used? 
e. How could it be improved? 
 
5. What did you think about the physiotherapy care you received whilst you were in 
hospital? 
 
6. You have received X (e.g. 3) sessions of physiotherapy since your operation in X (e.g. 
September), can you tell me what these sessions were like? 
a. PROBE: Can you remember any specific elements which stand out to you?  
b. Parts which were very useful for you? 
c. Made a big difference in your recovery from the surgery? 
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d. How and Why? 
e.  Any areas which were confusing or difficult? 
 
7. Can you tell me, were your appointments delivered via videocalls,  or face to face or a 
mixture of both? 
a. What was it like for you?  
b. Can you report any problems or difficulties you had with receiving your treatment 
face to face or via videocall? 
i. Probe physical  
1. e.g. did you have any technical problems with the video calls?  
2. e.g. Was it ok performing the physical movements and receiving the 
feedback from your physio via the video calls?  
ii. Probe psychological  
1. E.g. isolation or not feeling real at home  
2. E.g. exposing and stressful at clinic 
iii. Probe social 
1. E.g. can you have time in your home to do this or does family/others 
breech this privacy? 
 
8. Were there any sessions which you were unable to attend? Can you remember why you 
were unable to attend? Is there anything which the physiotherapy team could have done 
to make it easier for you to attend? 
a. Can you tell me about why you were not able to attend some sessions?  
i. Physical: radiotherapy/chemotherapy side-effects, pain, function, access, 
time? 
1. E.g. Were you feeling too tired or in pain? 
ii. Psychological: feeling low, unmotivated 
1. E.g. did they not feel that the programme was helping them? 
iii. Social: Had to look after children/work etc, radiotherapy/chemotherapy 
appointments? 
1. Was it the logistics? 
b. Do you think if you had received your physiotherapy sessions face to face or via 
videocall that this would have helped you more? 
c. Do you think anything could be changed to help with this problem? 
d. Would you have wanted more sessions? 
 
9. Did you think the physiotherapy sessions have helped you recover after your operation?  
a. We aim for the rehabilitation programme to help you to do the things you want to 
do to and lead the life you want. 
b. Probe physical (performing exercises, movement, fatigue, functioning?) 
c. psychological (value or exercise, embarrassment of visual disfigurement, confidence) 
d. social (isolated) 
i. Why do you think it helped? What has changed? Do you think it will last? 
What do you think you would feel like if you had not have attended these 
groups? 
ii. Why do you think it did not help? What would you suggest you should have 
been offered? 
 
10. Can you identify any specific parts of the sessions which stood out for you? Parts which 




a. Probe range of movement exercises (face neck and shoulder)- were these used? 
i. Probe how these helped 
ii. Swallowing 
iii. Upper limb mobility 
b. Probe progressive resistance training were these used? 
i. Probe how these helped 
ii. Gradually increasing difficulty 
iii. Strength 
c. Probe psychoeducation and behaviour change techniques aka what you talked 
about and some coping strategies which were used? 
i. Probe how these helped 
ii. Education e.g. positioning limbs, sleep, oral health, pain management, scar 
management,  
iii. exercise adherence - graded activities, fear avoidance, fatigue management, 
pacing, behaviour modification 
iv. promoting of independence and confidence 
 
11. Did the physio give you an exercise diary and/ or a printed set of physiotherapy for you to 
complete at home? (show examples) 
a. Can you remember what you received? 
b. Was this helpful? Can you describe how you used it (if you did)? 
c. Why and why not  
i. Probe capability:  
1. Physical: physically able to perform them? 
2. Psychological: did you feel that you were able to perform them?  
ii. Opportunity: 
1. Physical: Did you have space, time to perform physio exercises at 
home. Did you use the diary was it helpful? 
2. Social: family/friends support or not help i.e. not giving you 
space/time? 
iii. Motivation: 
1. Reflective: Did you think it was worth it? 
2. Automatic: worries about performing exercises? 
 
12. You completed a set of questionnaires before and after completing the GRRAND-F 
programme. What did you think about these questions? (Share the questionnaires to 
remind if nothing is remembered). 
a. Do they capture the issues which you think are important to you or were any issues 
that you think have been missed? 
i. Probe physical, psychological and social issues 
b. Were there any which you found difficult to complete? 
c. Any which you did not like? 
d. Were there too many or too few questionnaires? 
e. Did you complete them all and if not can you explain why – could the research team 
change them to make them better? 
f. Would you have liked to have used physical measures to test if your strength had 
improved? 
 
13. Have you sought any other type of help during your rehabilitation? outside of what we 
have offered you in this trial?  
a. Paid for other therapists? 
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b. Been referred within the NHS? 
 
14. Do you have any other feedback you would like to talk about.  
a. Things which we could change in how we deliver the programme?  
b. What is in the programme?  
c. How many sessions you receive?  





Introduction and rapport build before beginning recording. No right or wrong answers, 
take you time we want to learn as much as we can from you. You are the experts. Feel free to 
change your mind as we go along sometimes being asked different questions can make us 
realise we think different things. Please ask me questions before we begin or as we are 
chatting, this is not a formal interview it is just us talking to understand your experience. I am 
an independent person and our only aim to find out what is the best way we can help people 
rehabilitation after NC. 
 
1. What has it been like being part of this research study? (Opening broad question see what 
is the most pertinent issues which arise) 
a. Probe differences between different sites 
b. Difficulties and benefits 
c. Things you had wished you had known before agreeing to be part of the trial? 
 
2. Have you worked with this patient group (i.e. HNC NC rehab) before?  
a. Can you tell me how you felt before the study began? Any concerns?  
b. How you feel now you have been working with this group 
c. If you have been working with this groups previously, can you tell me if the patients 
who agreed to be part of this study were similar or different to the patients you 
have seen before? 
 
3. Can you tell me about the training you received before participating in this study? 
a. Bests bits 
b. Bits to change  
c. Bits to add 
d. Needed more / less? 
 
4. After you received your training in the GRRAND-F intervention, did you think this 
programme would help patients? 
a. Can you explain to me why/not? 
b. If you could change this programme what would you include/remove? 
i. Probe physical, psychological and social needs of patients 
 
5. Did you deliver the physiotherapy via videocalls, or face to face or a mixture of both? 
a. What was it like for you?  
b. Barriers/problems and facilitators with either modality 
i. Probe physical (observing exercises, technical issues) 
ii. Probe psychological (connection?) 
iii. Probe social 
c. Did you have appropriate space to deliver the GRRAND-F groups either via videocalls 
or face to face at your place of work 
 
6. Did you give you patients exercise diaries to monitor the physiotherapy they did at home?  
a. Did you think these were useful for you to know what was going on? 
b. Did you think they helped your patients? 
c. Can you offer any suggestions of how to change them? 
 
7. Did you give your patients handouts of physiotherapy activities for them to use at home?  
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a. Were these useful?  
b. Do you think they were they used? 
c. Can you suggest any improvements? 
 
8. Do you think/know that your patients practiced their physiotherapy exercises between 
sessions? Is there anything which you can suggest that the team do to improve 
adherence? 
a. Why and why not  
i. Probe capability: physical and psychological 
1. Do the patients understand and appreciate how important to their 
recovery it is to perform these physio exercises? 
2. Do they believe that they can perform these physio exercises? 
ii. Opportunity: probe physical and social 
1. Handouts to show them how to perform physio exercises 
2. Do they have time and support to do these rehab exercises? 
iii. Motivation: probe reflective and automatic 
1. Patients believe 
2. Patients fearful 
 
9. Did you experience many DNA and UTA appointments? 
a. Were these videocall or face to face appointments? 
b. Do you remember why your patients were unable to attend? 
c. Why do you think that was?  
d. Could we do anything to change the trial or intervention to alleviate this problem? 
 
10. If you focus on the contents of the GRRAND-F intervention now, what do you think are the 
most useful elements and any suggestions for changes? Can you talk me through what you 
think of… 
a. The range of movement exercises (face neck and shoulder)- were these used often, 
most?? 
i. Probe how these helped 
ii. Swallowing 
iii. Upper limb mobility 
b. Probe progressive resistance training were these used? 
i. Probe how these helped 
ii. Gradually increasing difficulty 
iii. Strength 
c. Probe psychoeducation and behaviour change techniques aka what you talked 
about and some coping strategies which were used? 
i. Probe how these helped 
ii. Education e.g. positioning limbs, sleep, oral health, pain management, scar 
management,  
iii. exercise adherence - graded activities, fear avoidance, fatigue management, 
pacing, behaviour modification 
iv. promoting of independence and confidence 
 
11. What do you think are the major barriers to implementing an intervention such as this 
into usual care? 
a. Workload 
b. Negative consequences? 




12. Do you think this programme has helped your patients?  
a. We aim for the rehabilitation programme to help your patients do the things they 
want to do to and lead the life they want. 
i. Probe physical (performing exercises, movement, fatigue, functioning?) 
ii. psychological (value or exercise, embarrassment of visual disfigurement, 
confidence) 
iii. social (isolated) 
b. Why do you think it helped? What has changed? Do you think it will last? What do 
you think they would feel like if they had not have attended these groups? 
c. Why do you think it did not help? What would you suggest you should have been 
offered? 
i. Probe for specific ideas 
 
 
13. Do you have any other feedback you would like to talk about.  
a. Things which we could change in how we deliver the programme?  
b. What is in the programme?  
c. How many sessions patients receive?  
d. What happens once your patients have finished the programme?  




Care as usual patient 
 
Introduction and rapport build before beginning recording. No right or wrong answers, 
take you time we want to learn as much as we can from you. You are the experts. Feel free to 
change your mind as we go along sometimes being asked different questions can make us 
realise we think different things. Please ask me questions before we begin or as we are 
chatting, this is not a formal interview it is just us talking to understand your experience. I am 
an independent person and our only aim to find out what is the best way we can help people 
rehabilitation after NC. 
 
1. Do you remember at what point you were approached about being part of this study?  
a. PROBE: cancer context (diagnosis), post-operative context and now continuing with 
the rest of their lives context (mortality, fear, job strain etc) 
b. How were you feeling?  
 
2. Can you tell me what you first thought about participating in a study like this?  
a. PROBE: positive (benefits) or negative (concerns i.e. volume of contact query) 
b. Can you recall anything that put you off agreeing to be part of the study?  
c. And / or was there anything, in particular, which made you keen to participate? 
 
3. When you were approached about the study were told that you might receive one type of 
physiotherapy or you might receive a different type. Can you tell me about these options? 
a. What can you remember? 
b. What did you think/feel about these options? 
 
4. Can you tell me about the physiotherapy you received during this trial? 
a. Was this what you were expecting? 
b. Did you hope to be in one group or another? 
c. How did you feel once you learnt what type of rehabilitation you would be 
receiving? 
 
5. When you were in hospital after your operation, do you remember the advice you 
received from the physiotherapist who worked with you? 
a. What do you remember from the advice? 
b. What did you think about the advice?  
c. What would you like to change? Or stay the same? 
 
6. When you were discharged from hospital after your operation, did you receive a booklet 
of physiotherapy exercises and an exercise diary to take home with you? 
a. Can you tell me what you thought about these? 
b. Were they useful? 
c. Have you performed any of these exercises? 
d. Do you think these should always be given out or not? 
 
d. Did you complete them all and if not can you explain why – could we change them? 
 
7. Did you think the advice you received in hospital and the booklet you took home with you 
helped you with your recovery?  
a. We aim for the rehabilitation programme to help you to do the things you want to 
do to and lead the life you want. 
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b. Probe physical (performing exercises, movement, fatigue, functioning?) 
c. psychological (value or exercise, embarrassment of visual disfigurement, confidence) 
d. social (isolated) 
i. Why do you think it helped? What has changed? Do you think it will last? 
ii. Why do you think it did not help? What would you suggest you should have 
been offered? 
 
8. Did you perform the physiotherapy and follow the advice in the booklet? Did you use the 
exercise diary? 
a. Why and why not  
iii. Probe capability: physical and psychological 
iv. Opportunity: probe physical and social 
v. Motivation: probe reflective and automatic 
 
9. Have you sought any other therapy outside of what this trial provided to help you in your 
rehabilitation? 
a. Referral within NHS 
b. Use of private services outside of NHS 
 
10. You completed a set of questionnaires (Share the questionnaires to remind if nothing is 
remembered). What did you think about these questions? 
a. Do they capture the issues which you think are important to you or were any issues 
that you think have been missed? 
vi. Probe physical, psychological and social issues 
b. Were there too many or too few questionnaires? 
c. Were there any you did not like? Did not wish to complete? 
d. Would you expect or want am objective measurement of physical strength to see if 
it is changing? 
 
11. Do you have any other feedback you would like to talk about.  
a. Did you seek any other advice/help outside of the programme? Or did you feel like 
you needed to? 
b. Things which we could change in how we deliver the programme?  
c. What is in the programme?  
d. How many sessions you receive?  
e. What happens once you have finished the programme?  
f. Or any other comments?
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Care as usual physio 
 
Introduction and rapport build before beginning recording. No right or wrong answers, 
take you time we want to learn as much as we can from you. You are the experts. Feel free to 
change your mind as we go along sometimes being asked different questions can make us 
realise we think different things. Please ask me questions before we begin or as we are 
chatting, this is not a formal interview it is just us talking to understand your experience. I am 
an independent person and our only aim to find out what is the best way we can help people 
rehabilitation after NC. 
 
1. What has it been like being part of this research study? (Opening broad question see what 
is the most pertinent issues which arise) 
a. Probe differences between different sites 
b. Difficulties and benefits 
c. Things you had wished you had known before agreeing to be part of the trial? 
 
2. Have you worked with this patient group (i.e. HNC NC rehab) before?  
a. Can you tell me how you felt before the study began? Any concerns?  
b. How you feel now you have been working with this group 
c. If you have been working with this groups previously, can you tell me if the patients 
who agreed to be part of this study were similar or different to the patients you 
have seen before? 
 
3. Can you tell me about the training you received before participating in this study? 
a. Bests bits 
b. Bits to change  
c. Bits to add 
d. Needed more / less? 
 
4. After you received your training, did you think the advice and information you were going 
to give to your patients would help them a lot, a little or not much? 
a. Can you explain to me why/not? 
 
5. Is the advice and information you delivered to the patients very different from what you 
usually do with this patient group?  
 
6. Did you give your patients the booklet and exercise diaries so that they could monitor 
their exercises at home?  
a. Did you think the discharge booklet was useful?  
b. Did you think the exercise diary was useful? 
c. Did you think they helped your patients? 
d. Can you offer any suggestions of how to change them? 
 
7. Do you think the advice and information has helped your patients a lot, a little or not 
much?  
a. Can you explain why or why not? 
 
8. Do you have any other feedback you would like to talk about.  
a. Things which we could change in how we run the study?  
b. What happens once your patients have finished the programme?  
c. Or any other comments? 
